Publications Maladie de Parkinson

-

  • Wassilios G Meissner 1, Philippe Remy 1, Caroline Giordana 1, David Maltête 1, Pascal Derkinderen 1, Jean-Luc Houéto 1, Mathieu Anheim 1, Isabelle Benatru 1, Thomas Boraud 1, Christine Brefel-Courbon 1, Nicolas Carrière 1, Hélène Catala 1, Olivier Colin 1, Jean-Christophe Corvol 1, Philippe Damier 1, Estelle Dellapina 1, David Devos 1, Sophie Drapier 1, Margherita Fabbri 1, Vanessa Ferrier 1, Alexandra Foubert-Samier 1, Solène Frismand-Kryloff 1, Aurore Georget 1, Christine Germain 1, Stéphane Grimaldi 1, Clémence Hardy 1, Lucie Hopes 1, Pierre Krystkowiak 1, Brice Laurens 1, Romain Lefaucheur 1, Louise-Laure Mariani 1, Ana Marques 1, Claire Marse 1, Fabienne Ory-Magne 1, Vincent Rigalleau 1, Hayet Salhi 1, Amandine Saubion 1, Simon R W Stott 1, Claire Thalamas 1, Claire Thiriez 1, Mélissa Tir 1, Richard K Wyse 1, Antoine Benard 1, Olivier Rascol 1; LIXIPARK Study Group. Trial of Lixisenatide in Early Parkinson's Disease. N Engl J Med. 2024 Apr 4;390(13):1176-1185

 

  • Laurencin C, Timestit N, Marques A, Duchez DD, Giordana C, Meoni S, Huddlestone M, Danaila T, Anheim M, Klinger H, Vidal T, Fatisson M, Caire C, Nourredine M, Boulinguez P, Dhelens C, Ballanger B, Prange S, Bin S, Thobois S. Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson's disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial. J Neurol. 2023 Jun 20.

     

  • Desjardins C, Nilles C, Devos D, Roze E. Apomorphine monotherapy for Parkinson's disease: A neglected option? J Mov Disord. 2023 Jun 9.

     

  • Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Růžička E, Dušek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garçon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group. Trial of Deferiprone in Parkinson's Disease. N Engl J Med. 2022 Dec 1;387(22):2045-2055. 

 

  • Rocha JF, Ebersbach G, Lees A, Tolosa E, Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Magalhães D, Gama H, Soares-da-Silva P. The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II. Front Neurol. 2022 Aug 23;13:994114.

 

  • Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, Postuma RB, Simon DK, Tolosa E, Mollenhauer B, Cedarbaum JM, Fraser K, Xiao J, Evans KC, Graham DL, Sapir I, Inra J, Hutchison RM, Yang M, Fox T, Budd Haeberlein S, Dam T; SPARK Investigators. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 Aug 4;387(5):408-420.

 

  • Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Moreira J, Pereira A, Rocha JF, Soares-da-Silva P. Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial. Neurol Ther. 2022 Sep;11(3):1409-1425. 

 

  • Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism Relat Disord. 2022 Mar;96:65-73. 

 

  • Rascol O, Medori R, Baayen C, Such P, Meulien D; AMBLED Study Group. A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease. Mov Disord. 2022 May;37(5):1088-1093. 

 

  • Tödt I, Al-Fatly B, Granert O, Kühn AA, Krack P, Rau J, Timmermann L, Schnitzler A, Paschen S, Helmers AK, Hartmann A, Bardinet E, Schuepbach M, Barbe MT, Dembek TA, Fraix V, Kübler D, Brefel-Courbon C, Gharabaghi A, Wojtecki L, Pinsker MO, Thobois S, Damier P, Witjas T, Houeto JL, Schade-Brittinger C, Vidailhet M, Horn A, Deuschl G. The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life. Mov Disord. 2022 Feb;37(2):291-301.

     

  • Rocha JF, Ebersbach G, Lees A, Tolosa E, Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Magalhães D, Gama H, Soares-da-Silva P. The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II. Front Neurol. 2021 Nov 5;12:754016.

 

  • Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Lockhart D, Staines H, Lees A. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord. 2021 Feb;83:79-85.

 

  • Poewe W, Volc D, Seppi K, Medori R, Lührs P, Kutzelnigg A, Djamshidian A, Thun-Hohenstein C, Meissner WG, Rascol O, Schneeberger A, Staffler G; AFF011 investigators; AFF011 study investigators:, Poewe W, Seppi K, Djamshidian A, deMarzi R, Heim B, Mangesius S, Stolz R, Wachowicz K, Volc D, Thun-Hohenstein C, Riha C, Schneeberger A, Bürger V, Galabova G. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. J Parkinsons Dis. 2021;11(3):1079-1089. 

 

  • Corvol JC, Azulay JP, Bosse B, Dauvilliers Y, Defebvre L, Klostermann F, Kovacs N, Maltête D, Ondo WG, Pahwa R, Rein W, Thobois S, Valis M, Videnovic A, Rascol O; THN102-202 Study Investigators. THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial. Mov Disord. 2021 Oct 28. 

 

  • Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, Bouchaoui H, Gouel F, Rolland AS, Duce JA, Devedjian JC; FAIRPARK-II and FAIRALS-II studygroups. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis. J Neural Transm (Vienna). 2020 Feb;127(2):189-203. 

 

  • Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C. Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020 Feb;71:4-10.

 

  • Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Long- term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol. 2019 Jul;26(7):953-960.

 

 

  • Corvol JC, Durif F, Meissner WG, Azulay JP, Haddad R, Guimarães-Costa R, Mariani LL, Cormier-Dequaire F, Thalamas C, Galitzky M, Boraud T, Debilly B, Eusebio A, Houot M, Dellapina E, Chaigneau V, Salis A, Lacomblez L, Benel L, Rascol O; French NS-Park/F-CRIN Network. Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial. Parkinsonism Relat Disord. 2018 Oct 4. pii: S1353-8020(18)30431-0. 

 

  • Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D; FAIRPARK-II study group. Iron as a therapeutic target for Parkinson's disease. Mov Disord. 2018 Apr;33(4):568-574.

 

  • Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo- controlled trial. Lancet Neurol. 2018 Sep;17(9):749-759. 

 

  • Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ; Preladenant Early Parkinson Disease Study Group. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. Neurology. 2017 Jun 6;88(23):2198-2206. 

     

  • Thibault L, Rascol O, Corvol JC, Ferreira J, Defebvre L, Deplanque D, Bordet R, Moreau C, Devos D. New perspectives on study designs for evaluating neuroprotection in Parkinson's disease. Mov Disord. 2017 Oct;32(10):1365-1370. 

     

  • Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW; AFU Investigators. Long-term effects of rasagiline and the natural history of treated Parkinson's disease. Mov Disord. 2016 Oct;31(10):1489-1496. 

 

  • Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O. A Phase 2A Trial of the  Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 Sep;31(9):1373-80.

 

  • Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Mov Disord. 2016 Jul;31(7):1049-54. 

 

  • Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O; NS-Park CIC Network. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014 Jan 28;82(4):300-7. 
  • Béreau M, Castrioto A, Lhommée E, Maillet A, Gérazime A, Bichon A, Pélissier P, Schmitt E, Klinger H, Longato N, Fraix V, Benatru I, Durif F, Azulay JP, Moro E, Broussolle E, Tranchant C, Anheim M, Thobois S, Krack P. Fatigue in de novo Parkinson's Disease: Expanding the Neuropsychiatric Triad? J Parkinsons Dis. 2022;12(4):1329-1337. 

 

  • Faggianelli F Jr, Loundou A, Baumstarck K, Nathalie S, Auquier P, Eusebio A, Defebvre L, Brefel-Courbon C, Houeto JL, Maltete D, Tranchant C, Derkinderen P, Geny C, Krystkowiak P, Jean-Philippe B, Macia F, Durif F, Poujois A, Borg M, Azulay JP, Witjas T; NS-Park FCRIN Network. Validation of a non-motor fluctuations questionnaire in Parkinson's disease. Rev Neurol (Paris). 2021 Sep 24:S0035-3787(21)00671-8.

 

  • Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S; COPARK Study Group. Correction to: Excessive buccal saliva in patients with Parkinson's disease of the French COPARK cohort. J Neural Transm (Vienna). 2021 Jun;128(6):871-872. doi: 10.1007/s00702-020-02264-1. Erratum for: J Neural Transm (Vienna). 2020 Dec;127(12):1607-1617.

 

  • Ihle J, Artaud F, Bekadar S, Mangone G, Sambin S, Mariani LL, Bertrand H, Rascol O, Durif F, Derkinderen P, Scherzer C, Elbaz A, Corvol JC; DIGPD study group Steering committee, . Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study. Parkinsonism Relat Disord. 2020 May 1;75:30-33.

 

  • Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S; COPARK Study Group. Excessive buccal saliva in patients with Parkinson's disease of the French COPARK cohort. J Neural Transm (Vienna). 2020 Dec;127(12):1607-1617. 

 

  • Phillipps C, Longato N, Béreau M, Carrière N, Lagha-Boukbiza O, Mengin AC, Monga B, Defebvre L, Ory-Magne F, Castrioto A, Lhommée E, Rascol O, Krack P, Tranchant C, Corvol JC, Anheim M. Is Motor Side Onset of Parkinson's Disease a Risk Factor for Developing Impulsive-Compulsive Behavior? A Cross-Sectional Study. Mov Disord. 2020 Jun;35(6):1080-1081. 

 

 

  • Marques A, Vidal T, Pereira B, Benchetrit E, Socha J, Pineau F, Elbaz A, Artaud F, Mangone G, You H, Cormier F, Galitstky M, Pomies E, Rascol O, Derkinderen P, Weintraub D, Corvol JC, Durif F; DIGPD study group. French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS). Parkinsonism Relat Disord. 2019 Jun;63:117-123. 

     

  • Cormier-Dequaire F, Bekadar S, Anheim M, Lebbah S, Pelissolo A, Krack P, Lacomblez L, Lhommée E, Castrioto A, Azulay JP, Defebvre L, Kreisler A, Durif F, Marques-Raquel A, Brefel-Courbon C, Grabli D, Roze E, Llorca PM, Ory-Magne F, Benatru I, Ansquer S, Maltête D, Tir M, Krystkowiak P, Tranchant C, Lagha-Boukbiza O, Lebrun-Vignes B, Mangone G, Vidailhet M, Charbonnier-Beaupel F, Rascol O, Lesage S, Brice A, Tezenas du Montcel S, Corvol JC; BADGE-PD study group. Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease. Mov Disord. 2018 Dec;33(12):1878-1886.

     

  • Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Tison F, Rascol O; of the COPARK Study Group. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. Eur J Neurol 2017 Dec ;24(12):1532-1538. 

     

  • Dujardin K, Auzou N, Lhommée E, Czernecki V, Dubois B, Fradet A, Maltete D, Meyer M, Pineau F, Schmitt E, Sellal F, Tison F, Vidal T, Azulay JP, Welter ML, Corvol JC, Durif F, Rascol O on behalf the NS-Park network. French consensus procedure for assessing cognitive function in Parkinson’s disease. Rev Neurol (Paris). 2016 Nov;172(11):696-702.

     

  • Rascol O, Perez-Lloret S, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Tison F, Negre-Pages L. Falls in ambulatory non-demented patients with Parkinson's disease. J Neural Transm (Vienna). 2015 Oct;122(10):1447-55.

     

  • Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Schelosky L, Tison F, Rascol O. Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. JAMA Neurol. 2014 Jul 1;71(7):884-90. 

 

  • Roze E, Hingray C, Degos B, Drapier S,  Tyvaert L, Garcin B, Carle-Toulemonde G. [Functional neurological disorders: A clinical anthology].Encephale. 2023 Aug;49(4S):S9-S17.

 

  • Prange S, Metereau E, Maillet A, Klinger H, Schmitt E, Lhommée E, Bichon A, Lancelot S, Meoni S, Broussolle E, Castrioto A, Tremblay L, Krack P, Thobois S. Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease. Mov Disord. 2022 Jun;37(6):1211-1221. 

 

  • Fabbri M, Leung C, Baille G, Béreau M, Brefel Courbon C, Castelnovo G, Carriere N, Damier P, Defebvre L, Doe de Maindreville A, Fluchere F, Fuzzatti M, Grabli D, Maltete D, Rousseau V, Sommet A, Thalamas C, Thiriez C, Rascol O, Ory-Magne F. A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study. Parkinsonism Relat Disord. 2021 Aug;89:128-133.

 

  • Lastennet D, Mariani LL, Rascol O, Turc JD, Alfaisal H, Lapeyre-Mestre M, Corvol JC, Tubach F. Evaluation of Prescription Practices of Domperidone in Parkinson's Disease: A Cross Sectional Study Among French Neurologists. CNS Drugs. 2020 Dec;34(12):1267-1274.

 

  • Ihle J, Artaud F, Bekadar S, Mangone G, Sambin S, Mariani LL, Bertrand H, Rascol O, Durif F, Derkinderen P, Scherzer C, Elbaz A, Corvol JC; DIGPD study group Steering committee, . Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study. Parkinsonism Relat Disord. 2020 May 1;75:30-33.

 

  • Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S; COPARK Study Group.  Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study. Drugs Aging. 2020 Mar;37(3):215-223.

 

  • Lee PC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques AR, Bourdain F, Brandel JP, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Brice A, Vidailhet M, Corvol JC, Elbaz A; DIGPD Study Group. Examining the Reserve Hypothesis in Parkinson's Disease: A Longitudinal Study. Mov Disord. 2019 Nov;34(11):1663-1671.
     
  • Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques AR, Bourdain F, Brandel JP, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Lee PC, Brice A, Vidailhet M, Elbaz A; DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018 Jul 17;91(3):e189-e201. 
  • Marques A, Macias E, Pereira B, Durand E, Chassain C, Vidal T, Defebvre L, Carriere N, Fraix V, Moro E, Thobois S, Metereau E, Mangone G, Vidailhet M, Corvol JC, Lehéricy S, Menjot de Champfleur N, Geny C, Spampinato U, Meissner WG, Frismand S, Schmitt E, Doé de Maindreville A, Portefaix C, Remy P, Fénelon G, Houeto JL, Colin O, Rascol O, Peran P, Bonny JM, Fantini ML, Durif F; R2* Study Group. Volumetric changes and clinical trajectories in Parkinson's disease: a prospective multicentric study. J Neurol. 2023 Aug 31.

 

  • Khedher L, Bonny JM, Marques A, Durand E, Pereira B, Chupin M, Vidal T, Chassain C, Defebvre L, Carriere N, Fraix V, Moro E, Thobois S, Metereau E, Mangone G, Vidailhet M, Corvol JC, Lehéricy S, Menjot de Champfleur N, Geny C, Spampinato U, Meissner W, Frismand S, Schmitt E, Doé de Maindreville A, Portefaix C, Remy P, Fénelon G, Luc Houeto J, Colin O, Rascol O, Peran P, Durif F; R study group. Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease. Neuroimage Clin. 2022;36:103231.

     

  • Prange S, Metereau E, Maillet A, Klinger H, Schmitt E, Lhommée E, Bichon A, Lancelot S, Meoni S, Broussolle E, Castrioto A, Tremblay L, Krack P, Thobois S. Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease. Mov Disord. 2022 Jun;37(6):1211-1221. 

     

  • Nemmi F, Pavy-Le Traon A, Phillips OR, Galitzky M, Meissner WG, Rascol O, Péran P. A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control. Neuroimage Clin. 2019;23:101858.

 

  • Péran P, Barbagallo G, Nemmi F, Sierra M, Galitzky M, Traon AP, Payoux P, Meissner WG, Rascol O. MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy. Mov Disord. 2018 Apr;33(4):600-608

  • Pablo Rabano-Su  arez,  1 Natalia del Campo,2 Isabelle Benatru, Caroline Moreau,Clément Desjardins, Alvaro S ´ anchez-Ferro, Margherita Fabbri. Digital Outcomes as Biomarkers of Disease Progression in Early Parkinson's Disease: A Systematic Review, Digital Outcomes as Biomarkers of Disease Progression in Early Parkinson's Disease: A Systematic Review - Rábano‐Suárez - Movement Disorders - Wiley Online Library

     

  • Margherita Fabbri, Vanessa Rousseau, Jean-Christophe Corvol, Agnès Sommet, Florence Tubach, Yann De Rycke, Nathalie Bertille, Yajiththa Selvarasa, Stephanie Carvalho, Véronique Chaigneau, Christine Brefel-Courbon, Fabienne Ory-Magne, Samuel Tessier, Melissa Tir, Matthieu Bereau, Wassilios G. Meissner, Claire Thiriez, Ana Marques, Philippe Remy, Vincent Schneider, Elena Moro, Luc Defebvre, Jean Luc Houeto, Stephane Prange, Alexandre Eusebio, Christian Geny, Solène Frismand, Philippe Damier, Caroline Giordana Reuther, Giovanni Castelnovo, Isabelle Benatru, Anne Doe De Maindreville, Sophie Drapier, David Maltête, Ouhaid Lagha-Boukbiza & Olivier Rascol for the French N. S.-Park network. Amantadine use in the French prospective NS-Park cohort. J Neural Transm (Vienna). 2024 Apr 5

 

  • Caroline Moreau, Tiphaine Rouaud, David Grabli, Isabelle Benatru, Philippe Remy, Ana-Raquel Marques, Sophie Drapier, Louise-Laure Mariani, Emmanuel Roze, David Devos, Gwendoline Dupont, Matthieu Bereau & Margherita Fabbri.Overview on wearable sensors for the management of Parkinson's disease. NPJ Parkinsons Dis. 2023 Nov 2;9

 

  • Virbel-Fleischman C, Mousin F, Liu S, Hardy S, Corvol JC, Benatru I, Bendetowicz D, Béreau M, De Cock VC, Drapier S, Frismand S, Giordana C, Devos D, Rétory Y, Grabli D. Symptoms assessment and decision to treat patients with advanced Parkinson's disease based on wearables data. NPJ Parkinsons Dis. 2023 Mar 27;9(1):45

 

  • Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, Defebvre L, Defer G, Dellapina E, Doé de Maindreville A, Geny C, Maltête D, Meissner WG, Rascol O, Thobois S, Torny F, Tranchant C, Vidailhet M, Corvol JC, Degos B; NS-Park/F-CRIN Network study group. Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort? Parkinsonism Relat Disord. 2019 Jul;64:226-234.

  • Mounir Alaoui O, Charbonneau PF, Prin P, Mongin M, Choquer M, Damier P, Riant F, Degos B. TMEM151A as an alternative to PRRT2 in paroxysmal kinesigenic dyskinesia: About three new cases. Parkinsonism Relat Disord. 2023 Mar;108:105295.

     

  • Cormier-Dequaire F, Bekadar S, Anheim M, Lebbah S, Pelissolo A, Krack P, Lacomblez L, Lhommée E, Castrioto A, Azulay JP, Defebvre L, Kreisler A, Durif F, Marques-Raquel A, Brefel-Courbon C, Grabli D, Roze E, Llorca PM, Ory-Magne F, Benatru I, Ansquer S, Maltête D, Tir M, Krystkowiak P, Tranchant C, Lagha-Boukbiza O, Lebrun-Vignes B, Mangone G, Vidailhet M, Charbonnier-Beaupel F, Rascol O, Lesage S, Brice A, Tezenas du Montcel S, Corvol JC; BADGE-PD study group. Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease. Mov Disord. 2018 Dec;33(12):1878-1886.

     

  • Dufournet B, Nguyen K, Charles P, Grabli D, Jacquette A, Borg M, Danaila T, Mutez E, Drapier S, Colin O, Eusebio A, Philip N, Azulay JP. Parkinson's disease associated with 22q11.2 deletion: Clinical characteristics and response to treatment. Rev Neurol (Paris). 2017 Jun;173(6):406-410.

     

  • Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison F, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D; Parkgait-II Study Group. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease. Brain. 2015 May;138(Pt 5):1271-83.
  • Matthieu Béreau, Astrid Kibleur, Mathieu Servant, Gautier Clément, Kathy Dujardin, Anne-Sophie Rolland, Thomas Wirth, Ouhaid Lagha-Boukbiza, Jimmy Voirin, Marie des Neiges Santin, Elodie Hainque, David Grabli, Alexandre Comte, Sophie Drapier, Franck Durif, Ana Marques, Alexandre Eusebio, Jean-Philippe Azulay, Caroline Giordana, Jean-Luc Houeto, Béchir Jarraya, David Maltete, Olivier Rascol, Tiphaine Rouaud, Mélissa Tir, Caroline Moreau, Teodor Danaila, Stéphane Prange, Laurent Tatu, Christine Tranchant, Jean-Christophe Corvol, David Devos, Stephane Thobois, Maxime Desmarets, Mathieu Anheim, for the Predistim Study Group. Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson's disease. Brain. 2023 Oct 3

 

  • Boussac M, Arbus C, Colin O, Laurencin C, Eusebio A, Hainque E, Corvol JC, Versace N, Rascol O, Rousseau V, Harroch E, Ory-Magne F, Fabbri M, Moreau C, Rolland AS, Jarraya B, Maltête D, Drapier S, Marques AR, Auzou N, Wirth T, Meyer M, Giordana B, Tir M, Rouaud T, Devos D, Brefel-Courbon C; PREDISTIM study group. Personality assessment with Temperament and Character Inventory in Parkinson's disease. Parkinsonism Relat Disord. 2022 Aug 19;103:34-41.

 

  • Betrouni N, Moreau C, Rolland AS, Carrière N, Viard R, Lopes R, Kuchcinski G, Eusebio A, Thobois S, Hainque E, Hubsch C, Rascol O, Brefel C, Drapier S, Giordana C, Durif F, Maltête D, Guehl D, Hopes L, Rouaud T, Jarraya B, Benatru I, Tranchant C, Tir M, Chupin M, Bardinet E, Defebvre L, Corvol JC, Devos D; PREDISTIM Study Group. Can Dopamine Responsiveness Be Predicted in Parkinson's Disease Without an Acute Administration Test? J Parkinsons Dis. 2022 Jul 18.

 

  • Prange S, Lin Z, Nourredine M, Danaila T, Laurencin C, Lagha-Boukbiza O, Anheim M, Klinger H, Longato N, Phillipps C, Voirin J, Polo G, Simon E, Mertens P, Rolland AS, Devos D, Metereau E, Tranchant C, Thobois S; Predistim study group. Limbic Stimulation Drives Mania in STN-DBS in Parkinson Disease: A Prospective Study. Ann Neurol. 2022 Sep;92(3):411-417.

 

  • Devignes Q, Daoudi S, Viard R, Lopes R, Betrouni N, Kuchcinski G, Rolland AS, Moreau C, Defebvre L, Bardinet E, Bonnet M, Brefel-Courbon C, Delmaire C, El Mountassir F, Fluchère F, Fradet A, Giordana C, Hainque E, Houvenaghel JF, Jarraya B, Klinger H, Maltête D, Marques A, Meyer M, Rascol O, Rouaud T, Tir M, Wirth T, Corvol JC, Devos D, Dujardin K; PREDISTIM working group. Heterogeneity of PD-MCI in Candidates to Subthalamic Deep Brain Stimulation: Associated Cortical and Subcortical Modifications. J Parkinsons Dis. 2022;12(5):1507-1526. 

 

  • Boussac M, Arbus C, Klinger H, Eusebio A, Hainque E, Christophe Corvol J, Rascol O, Rousseau V, Harroch E, d'Apollonia CS, Croiset A, Ory-Magne F, De Barros A, Fabbri M, Moreau C, Rolland AS, Benatru I, Anheim M, Marques AR, Maltête D, Drapier S, Jarraya B, Hubsch C, Guehl D, Meyer M, Rouaud T, Giordana B, Tir M, Devos D, Brefel-Courbon C; PREDISTIM study group. Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson's Disease (PSYCHO-STIM II). J Parkinsons Dis. 2022;12(2):699-711.

 

  • Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Croiset A, Ory-Magne F, Rascol O, Moreau C, Rolland AS, Maltête D, Rouaud T, Meyer M, Drapier S, Giordana B, Anheim M, Hainque E, Jarraya B, Benatru I, Auzou N, Belamri L, Tir M, Marques AR, Thobois S, Eusebio A, Corvol JC, Devos D, Brefel-Courbon C; PREDI-STIM study group. Personality dimensions of patients can change during the course of parkinson's disease. PLoS One. 2021 Jan 7;16(1):e0245142. 

 

  • Besse-Pinot E, Pereira B, Durif F, Fantini ML, Durand E, Debilly B, Derost P, Moreau C, Hainque E, Rouaud T, Eusebio A, Benatru I, Drapier S, Guehl D, Rascol O, Maltête D, Lagha-Boukbiza O, Giordana C, Tir M, Thobois S, Hopes L, Hubsch C, Jarraya B, Rolland AS, Corvol JC, Devos D, Marques A; Predistim study group. Preoperative REM Sleep Behavior Disorder and Subthalamic Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery. Neurology. 2021 Nov 16;97(20):e1994-e2006.

 

  • Santin MDN, Voulleminot P, Vrillon A, Hainque E, Béreau M, Lagha-Boukbiza O, Wirth T, Montaut S, Bardinet E, Kyheng M, Rolland AS, Voirin J, Drapier S, Durif F, Eusebio A, Giordana C, Auzou N, Houeto JL, Hubsch C, Jarraya B, Laurencin C, Maltete D, Meyer M, Rascol O, Rouaud T, Tir M, Moreau C, Corvol JC, Proust F, Grabli D, Devos D, Tranchant C, Anheim M; Predistim Study Group. Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study. Mov Disord. 2021 Mar;36(3):750-757.

Partager

Mis à jour le 19 décembre 2024